Today: 7 February 2026
Subscribe
Browse Category

NYSE:DAVA News 11 November 2025 - 13 November 2025

Paysafe (PSFE) Tumbles After Q3 2025 Earnings Miss, Guidance Cut and New Endava AI Partnership

Paysafe (PSFE) Tumbles After Q3 2025 Earnings Miss, Guidance Cut and New Endava AI Partnership

London / New York – November 13, 2025 — Paysafe Limited (NYSE: PSFE) is in the spotlight today after releasing its third‑quarter 2025 results, slashing its full‑year outlook and unveiling a new multi‑year AI‑driven payments partnership with Endava. The mixed update has triggered a sharp sell‑off in PSFE stock despite solid underlying revenue growth. Stock Titan+2 Key takeaways for PSFE today (13 November 2025) Q3 2025 results: modest growth, big tax hit Paysafe’s Q3 2025 revenue came in at $433.8 million, a 2% increase from the same quarter last year. This growth came despite a roughly $24 million revenue headwind
13 November 2025
··
Endava (DAVA) Sinks After Q1 FY26 Miss; FY26 Outlook Trimmed as Company Expands TRD U.S.A. Partnership — Nov 11, 2025

Endava (DAVA) Sinks After Q1 FY26 Miss; FY26 Outlook Trimmed as Company Expands TRD U.S.A. Partnership — Nov 11, 2025

Endava plc (NYSE: DAVA) reported weaker‑than‑expected first‑quarter fiscal 2026 results before the U.S. market open today and cut its full‑year guidance. Shares fell sharply in early trading as investors digested a year‑over‑year revenue decline and softer outlook; the company also announced an expanded multi‑year partnership with Toyota Racing Development (TRD U.S.A.). Business Wire+3Business Wire+3MarketWatch+3 Quick takeaways By the numbers: Q1 FY26 (quarter ended Sept 30, 2025) Business mix & clients. Endava ended the quarter with 11,636 total headcount; 133 clients generated over £1M on a rolling‑12‑month basis. Revenue mix: North America 42%, UK 28%, Europe 24%, RoW 6%. By industry:
11 November 2025
··

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop